Meta-analysis results identify high and low associations of various comorbidities like vitamin D deficiencies, ocular diseases, among others in patients with alopecia areata (AA), to promptly manage and improve treatment outcomes.
Artificial intelligence-powered eye-aging clock facilitates the tracking of ocular aging, revealing new potential target therapies for a range of eye disorders.
In its second big pharma deal to date, Shape Therapeutics Inc. drew Otsuka Pharmaceutical Co. Ltd. to the table in a potential $1.5 billion-plus collaboration initially aimed at developing gene therapies for ocular diseases. The multitarget agreement, which includes options for additional targets and tissue types, will combine Shape’s AI-driven adeno-associated virus (AAV) platform and Otsuka’s expertise in ophthalmology to develop intravitreally delivered AAV therapies.
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.